NEW YORK – Owkin and Proscia said Tuesday that the firms have inked a deal to make Owkin's colorectal cancer diagnostic test available through Proscia's digital pathology software platform.
Paris-based Owkin's MSIntuit CRC v2 is an artificial intelligence-developed screening test that is used to identify microsatellite instability and aid the management of colorectal cancer, and it is an updated version of the company's CE-IVD marked MSIntuit CRC test. The results can help healthcare providers to identify patients who are eligible for treatment with immune checkpoint inhibitors or chemotherapy.
Financial and other terms of the deal were not disclosed.
Philadelphia-based Proscia said that it will integrate the colorectal cancer test into its Proscia Concentriq software platform as part of a precision medicine testing portfolio.
"Our shared focus on advancing pathology from drug discovery to diagnostics uniquely positions us to unlock the potential of AI on novel therapies and treatment decisions, and our growing base of customers will ensure that breakthroughs are translated into the clinic to benefit patients," Proscia CEO David West said in a statement.
The firms noted that Owkin's MSIntuit CRC v2 screening test is currently for research use only in the US, and in Europe, the test is under development and will be submitted for CE-IVDR marking.
As part of the collaboration, Owkin has also joined the Proscia Ready interoperability alliance that Proscia launched earlier this year to assure diagnostic labs and life science firms that hardware and software components from alliance members will work together as seamlessly as possible.